KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $11.8 million.

  • Adaptive Biotechnologies' Net Cash Flow rose 15446.68% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year increase of 13294.51%. This contributed to the annual value of -$17.2 million for FY2024, which is 2968.65% up from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Net Cash Flow of $11.8 million as of Q3 2025, which was up 15446.68% from -$7.5 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Net Cash Flow peaked at $141.1 million during Q3 2022, and registered a low of -$127.6 million during Q4 2022.
  • Its 5-year average for Net Cash Flow is -$3.6 million, with a median of $2.5 million in 2025.
  • Data for Adaptive Biotechnologies' Net Cash Flow shows a peak YoY increase of 32841.63% (in 2022) and a maximum YoY decrease of 86546.45% (in 2022) over the last 5 years.
  • Adaptive Biotechnologies' Net Cash Flow (Quarter) stood at $16.7 million in 2021, then plummeted by 865.46% to -$127.6 million in 2022, then skyrocketed by 81.47% to -$23.6 million in 2023, then skyrocketed by 141.27% to $9.8 million in 2024, then increased by 21.37% to $11.8 million in 2025.
  • Its Net Cash Flow stands at $11.8 million for Q3 2025, versus -$7.5 million for Q2 2025 and $2.5 million for Q1 2025.